Aurinia to Participate in Jefferies London Healthcare Conference

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the Jefferies Healthcare Conference in London, November 19-21, 2024.

Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Wednesday, November 20, at 12:00 PM GMT/7:00 AM EST. This session will not include a webcast.

About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).

View source version on businesswire.com: https://www.businesswire.com/news/home/20241114401812/en/

Media & Investor Inquiries:
Andrea Christopher
Corporate Communications & Investor Relations
Aurinia Pharmaceuticals Inc.
[email protected]

General Investor Inquiries:
[email protected]

Source: Aurinia Pharmaceuticals Inc.

You May Also Be Interested In

• NCC's Executive Director and Psychometrician Bresney Fanning Assumes Presidency of the American Board of Nursing Specialties (ABNS)
• Sergio V. Crowley Publishes Operations Research Framework for Industrial Capital Deployment
• Back-to-School Meets the US Open: PINSPARK Delivers “Campus-to-Court” Style with Fabric Innovation